Tourmaline Bio Overview
Latest P/E ratio for Tourmaline Bio: -26.8 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-26.80
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for TRML is -26.8. That is below the Healthcare sector average of 27.42. Investors often review this figure alongside Tourmaline Bio's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, TRML currently prints -26.8 for P/E ratio, while the sector average sits near 27.42. That is roughly 197.7% below the sector mean. Large gaps often invite a closer look at Tourmaline Bio's growth, margins, and balance sheet.
A P/E ratio of -26.8 for Tourmaline Bio is not 'good' or 'bad' on its own. Compare it with the peer average (27.42) and with TRML's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting TRML's P/E ratio (-26.8), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Tourmaline Bio's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
